Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the functionality of the GastroPlus platform.
The collaboration focuses on enhancing the predictive capabilities of the GastroPlus advanced compartmental absorption and transit (ACAT™) model to support the development of immediate release (IR) oral drug products. Using data gathered from public sources and members of the ETC, physiologically based pharmacokinetics (PBPK) and biopharmaceutics modeling (PBBM) experts and software engineers at Simulations Plus will look to complete key objectives as defined by the partnership. These advancements, including implementation of novel product-particle size distribution (P-PSD) methodologies and enhanced food effect modeling features, will provide researchers with powerful tools to improve drug product development, reduce reliance on animal studies, and streamline regulatory submissions.
“We are honored to collaborate with ETC, a consortium representing leaders in pharmaceutical innovation who recognize the critical role GastroPlus already plays in drug development,” said Dr. Xavier Pepin, Vice President of PBPK R&D at Simulations Plus and principal investigator for this project. “This partnership reflects the trust and confidence the industry places in our platform and the desire to support its continued evolution. By advancing cutting-edge capabilities, we are not only reaffirming our commitment to innovation but also empowering researchers to solve complex biopharmaceutical challenges with even greater precision and efficiency.”
The collaboration leverages the combined expertise of Simulations Plus and ETC’s Participating Members, which include leading pharmaceutical and biotechnology companies. Throughout the project, Simulations Plus will deliver beta versions of the enhanced GastroPlus platform to ETC members for testing. Upon completion, the updated software will be accessible to the broader user community. Consistent with all collaborations that Simulations Plus enters, the Company will retain ownership of intellectual property developed through this partnership, ensuring that future enhancements to its platform continue to reflect Simulations Plus’ leadership in PBPK/PBBM science.